Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview: Diabetes • Diagnosis of diabetes • Complications associated with high blood glucose levels PART 06: Pipeline portfolio • Pipeline for new drug application (NDA) filings • Pipeline for Phase III molecules • Pipeline for Phase II molecules • Pipeline for Phase I molecules • Pipeline for pre-clinical stage molecules • Pipeline for discovery stage molecules PART 07: Market landscape • Market overview • Five forces analysis PART 08: Overview of marketed products • Synopsis of key diabetic drugs • Marketed product profiles PART 09: Market segmentation by type of disease • Global type 1 diabetes market • Global type 2 diabetes market • Global gestational diabetes market PART 10: Market segmentation by drug class • Insulin therapies • Non-insulin therapies PART 11: Geographical segmentation • Diabetic therapeutic market in Americas • Diabetic therapeutic market in US • Diabetic therapeutic market in EMEA • Diabetic therapeutic market in Europe • Diabetic therapeutic market in Germany • Diabetic therapeutic market in UK • Diabetic therapeutic market in France • Diabetic therapeutic market in Italy • Diabetic therapeutic market in Spain • Diabetic therapeutic market in APAC • Diabetic therapeutic market in China • Diabetic therapeutic market in India PART 12: Market drivers4 • Change in patient preference • Focus on self-management of diabetes • The strong potential of biologics • Unmet medical needs and scope for DMDs PART 13: Impact of drivers PART 14: Market challenges • Complex storage conditions and distribution policies for insulin • Unpredictable outcomes on human due to lack of predictable animal models • Gap in nation-level diabetes management plans • Rising concerns in the scientific community PART 15: Impact of drivers and challenges PART 16: Market trends • Focus on oral insulin therapies • Growing technological integration fueling the market growth • Focus on regenerative medicines • Strong and diversified pipeline portfolio PART 17: Vendor landscape8 • Competitive scenario • Market analysis 2016 • Upcoming vendors for oral insulin therapies • Oramed Pharmaceuticals • Generex Biotechnology • Other prominent vendors PART 18: Key vendor analysis • Novo Nordisk • Sanofi • Merck • Eli Lilly • AstraZeneca PART 19: Appendix • List of abbreviations PART 20: Explore Technavio     List of Exhibits Exhibit 01: Product offerings Exhibit 02: Types of diabetes Exhibit 03: Diagnosis of diabetes Exhibit 04: Market share of pipeline molecules Exhibit 05: NDA filings: Global diabetic therapeutic market Exhibit 06: Phase III pipeline portfolio: Global diabetic therapeutic market Exhibit 07: Phase II pipeline portfolio: Global diabetic therapeutic market Exhibit 08: Phase I pipeline portfolio: Global diabetic therapeutic market Exhibit 09: Pre-clinical pipeline portfolio: Global diabetic therapeutic market Exhibit 10: Pipeline portfolio for discovery stage molecules: Global diabetic therapeutic market Exhibit 11: Market snapshot of global diabetic therapeutic market 2016-2021 Exhibit 12: Overview of global diabetic therapeutic market 2016-2021 Exhibit 13: Global diabetic therapeutic market 2016-2021 ($ billions) Exhibit 14: Prospects of the global diabetic therapeutic market Exhibit 15: Vendors' strategies and the un-addressed needs for global diabetic therapeutic market Exhibit 16: Global diabetic therapeutic market snapshot: Developed and emerging markets 2016 Exhibit 17: Factors affecting the insulin therapies Exhibit 18: Global diabetic therapeutic market: Present and outlook and its impact Exhibit 19: Five forces analysis Exhibit 20: Information on key marketed diabetic drugs Exhibit 21: Product profiles of marketed products: Standard insulin therapies Exhibit 22: Product profiles for marketed products: Non-insulin therapies - DPP-4 class Exhibit 23: Product profiles for marketed products: Non-insulin therapies - GLP-1 class Exhibit 24: Product profiles for marketed products: Non-insulin therapies - SGLT2s class Exhibit 25: Segmentation of global diabetic therapeutic market by type of disease (2016) Exhibit 26: Market overview of global type 1 diabetes market 2016-2021 Exhibit 27: Opportunity analysis of global type 1 diabetes market Exhibit 28: Global type 1 diabetes market 2016-2021 ($ billions) Exhibit 29: Market overview of global type 2 diabetes market 2016-2021 Exhibit 30: Opportunity analysis of global type 2 diabetes market Exhibit 31: Global type 2 diabetes market 2016-2021 ($ billions) Exhibit 32: Global gestational diabetes market 2016-2021 ($ billions) Exhibit 33: Overview of global diabetic therapeutic market by drug class, 2016 Exhibit 34: Snapshot of global diabetic therapeutics market by geography Exhibit 35: Global diabetes therapeutics market segmentation by region: Market growth lifecycle analysis 2016 Exhibit 36: Diabetic therapeutic market revenue by geography 2016-2021 ($ billions) Exhibit 37: Overview of diabetic therapeutic market in Americas Exhibit 38: Diabetic therapeutic market in Americas 2016-2021 ($ billions) Exhibit 39: Overview of diabetic therapeutic market in US Exhibit 40: Opportunity analysis: Diabetic therapeutic market in US Exhibit 41: PESTLE analysis: Diabetic therapeutic market in US Exhibit 42: Overview of diabetic therapeutic market in EMEA Exhibit 43: Diabetic therapeutic market in EMEA 2016-2021 ($ billions) Exhibit 44: Share of diabetic therapeutic market in EMEA 2016 Exhibit 45: Overview of diabetic therapeutic market in Europe Exhibit 46: Diabetic therapeutic market: Regional outlook of Europe, 2016 and 2021 Exhibit 47: Opportunity analysis: Diabetic therapeutic market in Europe Exhibit 48: PESTLE analysis: Diabetic therapeutic market in Europe Exhibit 49: Overview of diabetic therapeutic market in Germany Exhibit 50: Opportunity analysis: Diabetic therapeutic market in Germany Exhibit 51: Overview of diabetic therapeutic market in UK Exhibit 52: Opportunity analysis: Diabetic therapeutic market in UK Exhibit 53: Overview of diabetic therapeutic market in France Exhibit 54: Opportunity analysis: Diabetic therapeutic market in France Exhibit 55: Overview of diabetic therapeutic market in Italy Exhibit 56: Opportunity analysis: Diabetic therapeutic market in Italy Exhibit 57: Overview of diabetic therapeutic market in Spain Exhibit 58: Opportunity analysis: Diabetic therapeutic market in Spain Exhibit 59: Overview of diabetic therapeutic market in APAC Exhibit 60: Diabetic therapeutic market: Regional outlook, APAC, 2016 and 2021 Exhibit 61: Diabetic therapeutic market in APAC 2016-2021 ($ billions) Exhibit 62: Overview of diabetic therapeutic market in China Exhibit 63: Opportunity analysis: Diabetic therapeutic market in China Exhibit 64: Pest analysis: Diabetic therapeutic market in China Exhibit 65: Overview of diabetic therapeutic market in India Exhibit 66: Opportunity analysis: Diabetic therapeutic market in India Exhibit 67: PESTLE analysis: Diabetic therapeutic market in India Exhibit 68: Impact of drivers and challenges in global diabetes therapeutic market Exhibit 69: Impact of drivers Exhibit 70: Impact of drivers and challenges Exhibit 71: Impact of trends in global diabetic therapeutic market Exhibit 72: Oral insulin pipeline portfolio Exhibit 73: Key technological integrations Exhibit 74: Regenerative medicines under development for the treatment of diabetes Exhibit 75: Competitive structure analysis of global diabetic therapeutic market 2016 Exhibit 76: Top-selling diabetic therapeutics based on sales 2015 ($ billions) Exhibit 77: Geographical presence of key vendors Exhibit 78: Competitive scenario: Global diabetic therapeutic market vendors 2016-2021 Exhibit 79: Oramed Pharmaceuticals: Pipeline products Exhibit 80: Novo Nordisk: Key products in diabetes market Exhibit 81: Novo Nordisk: Profile Exhibit 82: Novo Nordisk: Strength analysis Exhibit 83: Novo Nordisk: Strategy assessment Exhibit 84: Novo Nordisk: Opportunity assessment Exhibit 85: Sanofi: Key product offerings in diabetes market Exhibit 86: Sanofi: Profile Exhibit 87: Sanofi: Strength analysis Exhibit 88: Sanofi: Strategy assessment Exhibit 89: Sanofi: Opportunity assessment Exhibit 90: Merck: Profile Exhibit 91: Merck: Strength analysis Exhibit 92: Merck: Strategy assessment Exhibit 93: Merck: Opportunity assessment Exhibit 94: Eli Lilly: Top-selling diabetic drugs in 2015 Exhibit 95: Eli Lilly: Profile Exhibit 96: Eli Lilly: Strategy assessment Exhibit 97: Eli Lilly: Opportunity assessment Exhibit 98: AstraZeneca: Top-selling diabetes drugs in 2015 Exhibit 99: AstraZeneca: Profile9 Exhibit 100: AstraZeneca: Strength analysis Exhibit 101: AstraZeneca: Strategy assessment Exhibit 102: AstraZeneca: Opportunity assessment

AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi, AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, Amgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDM, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind Corporation, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, Norgine, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix BioTherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, Sun Pharma, Takeda Pharmaceuticals, Teva, Thera Technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, Zydus Cadila.